26 July 2023

BioCurate and EDDC Signs MoU To Announce Strategic Alliance

EDDC has signed a MoU with BioCurate to bring together complementary scientific and business development expertise and explore opportunities for co-development on projects with the potential to enter the market as new commercially viable therapies.

Click here to read the announcement.

EBC-129: Phase 1 study of our first-in-class, anti N-glycosylated CEACAM5 & 6 ADC in solid tumours

Partex and Singapore’s Experimental Drug Development Centre collaborate to bring forward an innovative approach for early drug discovery and development

First Made-in-Singapore Antibody-Drug Conjugate EBC-129 progresses to Phase 1B Dose Expansion

Share

BioCurate and EDDC Signs MoU To Announce Strategic Alliance

Related Articles

EBC-129: Phase 1 study of our first-in-class, anti N-glycosylated CEACAM5 & 6 ADC in solid tumours

Partex and Singapore’s Experimental Drug Development Centre collaborate to bring forward an innovative approach for early drug discovery and development

First Made-in-Singapore Antibody-Drug Conjugate EBC-129 progresses to Phase 1B Dose Expansion

Helpful Links

Contact Us